The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy
View original at finance.yahoo.com“Keytruda Revenue ($B) $29.5 $31.5 $32.7 $33.0”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
CAPVAXIVE reached $240M+ quarterly revenue by Q3 2025
80% confidenceMerck has committed over $70 billion to U.S. manufacturing and R&D
80% confidenceConsensus analyst price target for MRK stands at $118 (average), with a high of $139
80% confidenceMRK fair value is $138 using 15x P/E on FY2026 EPS of $9.20; price target of $130 after 5% execution risk discount
80% confidenceThe global PAH therapeutics market totaled $7.65 billion in 2024 and is projected to reach $9.35 billion by 2034
80% confidenceIn a bull case, where Non-Keytruda revenue grows at 12% and the cost program delivers +150 basis points of margin expansion, MRK fair value approaches $145-150
80% confidenceThis represents a near-tripling of Phase III pipeline depth since 2021
80% confidenceFY2025 Non-Keytruda revenue drag reflects GARDASIL China inventory destocking as a one-time headwind; underlying ex-China growth remains positive
80% confidenceMerck's 9.4x EV/EBITDA multiple implies the market is pricing in excessive LOE risk that management's diversification strategy is actively and successfully mitigating
80% confidenceBMO Capital upgraded MRK to a $130 price target
80% confidenceIRA pricing pressure creates approximately $400 million in annual headwind, primarily affecting WINREVAIR and small molecule oncology products
80% confidenceThe Merck-Moderna mRNA-4157 partnership represents perhaps the most watched collaboration in biotech
80% confidenceKeytruda biosimilars expected to cause 15-30% price erosion in the EU by Year 3 post-LOE and 10-25% in the U.S.
80% confidenceMerck is executing one of the most comprehensive lifecycle management and portfolio diversification strategies in recent pharmaceutical history
80% confidenceKeytruda generated $29.5 billion in FY2024, representing 46% of total revenue and making it the world's best-selling pharmaceutical product
80% confidenceMerck commands the highest operating margin (33.7%) and strongest revenue growth (7%) among traditional large-cap pharma peers
80% confidenceMerck currently has approximately 80 Phase III clinical trials underway across therapeutic areas including oncology, cardiovascular disease, infectious diseases, and immunology
80% confidenceWINREVAIR's peak sales potential could expand from $3-4 billion (PAH only) to $6-8 billion if HFpEF indications are successfully developed and approved
80% confidenceManagement has identified 20+ pipeline assets with blockbuster potential, projecting a cumulative $50+ billion revenue opportunity by the mid-2030s
80% confidenceThe $3B cost program will deliver $1.7B in annual savings by 2027 through manufacturing optimization, real estate reduction, and headcount rationalization
80% confidenceWINREVAIR achieved $419M in FY2024 revenues and is projected to exceed $1B cumulative by late 2025
80% confidence